bispecific-antibodies-antibody-38.html
Novo Annual Report 2015
39 / 72
h l vha vhb vl vl cl cl ch1 ch1 ch2
ch3
ch2
ch3
consistent domains variable domains heavy
chain
light
chain
human bioclonics ® the bispecific format with same light
chain
and different heavy
chain
s. in the
ch3
region, two specific mutations give electrostatic repulsion/attraction between the different backbones to ensure hetero-dimerisation. novo ventures a field with great promise in recent years, various cancer immunotherapy approaches have shown impressive clinical benefits to patients. bispecific antibodies are poised to play an important role in cancer immuno-therapy since they hold the promise of effectively redirecting a patient's immune response to specific tumour cells with the convenience of easy to use ?off-the-shelf? antibody products. to carry out its long-term vision, merus requires a strong and committed financial base. this year, sofinnova ventures and novo co-led the company?s eur 72.8
million
series c round to finance advancement into human clinical studies. fast facts on merus privately held company number of employees: 36 located in utrecht, netherlands raised euro 100
million
in vc and public financing. novo led the series c round of euro 73
million
. annual review 2015 39
zio-cardiac-service-40.html
